Scrip is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Chasing Pfizer, Sarepta Prepares To Launch Pivotal Duchenne Gene Therapy Trial

Investors Still Skeptical

Executive Summary

Sarepta believes it is still very much in the running with its gene therapy but is playing down talk of an accelerated approval based on biomarker data.

You may also be interested in...



Sarepta Leapfrogs Pfizer In The US, Launching DMD Gene Therapy Pivotal Trial

The company has initiated the first pivotal double-blind gene therapy trial in DMD in the US in a tight race with Pfizer.

Sarepta Sinks On Mixed DMD Gene Therapy Study

Any time advantage Sarepta's Duchenne muscular dystrophy gene therapy may have had over rivals, notably Pfizer, has disappeared after SRP-9001 failed to significantly improve muscle function in a closely watched trial.

Potential For Functional Cure Opens Up With GSK’s Hepatitis B Candidate

Bepirovirsen made the hepatitis B virus undetectable in nearly 30% of patients in a Phase II study – but it remains to be seen whether this response be sustained once treatment with the novel antisense product ends.

Topics

Related Companies

Latest News
UsernamePublicRestriction

Register

SC144850

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Thank you for submitting your question. We will respond to you within 2 business days. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel